Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies-Reference-Cited by-同舟云学术

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies

Published:2017-03-29 Issue:11 Volume:45 Page:1390-1402
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sanyal A. J.¹^ORCID,Boyer T. D.²,Frederick R. T.³,Wong F.⁴,Rossaro L.⁵,Araya V.⁶,Vargas H. E.⁷,Reddy K. R.⁸,Pappas S. C.⁹,Teuber P.⁹,Escalante S.¹⁰,Jamil K.¹⁰

Affiliation:

1. Department of Medicine; Virginia Commonwealth University; Richmond VA USA

2. Department of Medicine; University of Arizona; Tucson AZ USA

3. Department of Transplantation; California Pacific Medical Center; San Francisco CA USA

4. Department of Medicine; University of Toronto; Toronto ON Canada

5. University of California Davis; Sacramento CA USA

6. Department of Gastroenterology and Hepatology; Central Bucks Specialists, Ltd.; Doylestown PA USA

7. Division of Gastroenterology and Hepatology; Mayo Clinic Arizona; Phoenix AZ USA

8. Division of Gastroenterology and Hepatology; Department of Medicine; University of Pennsylvania; Philadelphia PA USA

9. Orphan Therapeutics; Lebanon NJ USA

10. Ikaria Therapeutics LLC/a Mallinckrodt Company; Hampton NJ USA

Funder

Ikaria Therapeutics LLC/a Mallinckrodt Company

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14052/fullpdf

Reference27 articles.

1. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis;Salerno;Gut,2007

2. Recent advances in our understanding of hepatorenal syndrome;Wong;Nat Rev Gastroenterol Hepatol,2012

3. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis;Fagundes;Am J Kidney Dis,2012

4. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation;Alessandria;Hepatology,2005

5. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation;Wong;Liver Transpl,2015

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Mortality Rates of Vasoconstrictor Agents in the Management of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis;Cureus;2024-08-16

2. Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review;Journal of Clinical and Translational Hepatology;2024-07-25

3. EVIDENCE-BASED GUIDELINES FOR THE USE OF ALBUMIN PRODUCTS (REVISED THIRD EDITION);Japanese Journal of Transfusion and Cell Therapy;2024-06-25

4. Management of hepatorenal syndrome and associated outcomes: a systematic review;BMJ Open Gastroenterology;2024-04

5. Terlipressin for hepatorenal syndrome;Current Opinion in Gastroenterology;2024-03-07